Parkinson's Disease: Immunometabolic Control Points Across Neural, Vascular, and Peripheral Systems.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts without systematic methodology or primary data
PubMed 42614481 · doi:10.1155/padi/5349481
What was done
This narrative review synthesized experimental, clinical, and pharmacological literature to propose a framework wherein Parkinson's disease is driven by chronic immunometabolic dysregulation across neural, vascular, and peripheral systems.
What was found
The abstract reports no empirical numbers or quantitative data. It conceptually outlines key immunometabolic control points, including microbial immune priming, gut-brain axis interactions, platelet-derived inflammatory signaling and amyloid-beta release, immune checkpoint disruption via the PD-1/PD-L1 axis, and NAMPT-dependent NAD+ salvage pathways.
Why it matters
Reframing Parkinson's disease around upstream multisystem immunometabolic failure identifies potential disease-modifying therapeutic targets prior to irreversible dopaminergic neuronal loss.
Limits
As a narrative review, this work provides no new empirical data, systematic search criteria, or quantitative synthesis. Many cited relationships derive from experimental models or mechanistic hypotheses that require rigorous clinical validation.
Cited by
- supports In Parkinson's disease, dopaminergic neurons in the substantia nigra of the midbrain die.